Find Funding Opportunities

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinsons Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited (rapid) funding mechanism for research on Zika virus (ZIKV) and its complications.ZIKV is a single-stranded RNA virus of the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes mosquitos, though both perinatal/in utero and sexual transmission have been reported.Initially discovered in 1947, it has been reported in the Americas since 2014, with a major outbreak in Brazil starting in 2015.Disease is seen in about 20% of infected people and is usually self-limited.However, a possible association between ZIKV infection in pregnant women and severe microcephaly in their babies has been very concerning and prompted the World Health Organization to declare this potential complication a public health emergency. Additionally the virus has been found in blood, fueling growing concerns about the risk of transfusion-transmissionwith particular concern over severe outcomes in at risk transfusion recipient populations such as women who are pregnant.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease of vascular origin including multifocal, small, and silent brain infarcts that may contribute to cognitive impairment and dementia.

This Funding Opportunity Announcement (FOA) is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov/), a collaborative and coordinated effort across 13 Institutes and Centers that support research, research education, and research training with the goal of accelerating the pace of discovery in neuroscience research. This FOA will support integrated research education and research training programs that provide interdisciplinary training in experimental neuroscience and the theoretical and technological approaches of computational neuroscience at the undergraduate and predoctoral level.

The purpose of this FOA is to support the Neuroimaging Informatics Tools and Resources Clearinghouse and to enable collaborative research in neuroimaging informatics

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain.The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical study (e.g., Early Feasibility Study).Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical study. The small clinical study should provide data to answer key questions about the function or final design of a device.This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.The clinical study is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue a small clinical study to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and thereby better understand the human brain (e.g., Early Feasibility Study).Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.The clinical study should provide data to answer key questions about the function or final design of a device.This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.The clinical study is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical study to answer key questions about the function or final design of a device.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of allergy, immunology, and infectious diseases including HIV/AIDS and its co-morbidities and co-infections, mental health, and selected neurological disorders.